Human Genomics, published by BMC, is a leading open-access journal dedicated to advancing the field of genomics and its applications in health and disease. Since its inception in 2003, the journal has provided a vital platform for researchers to disseminate groundbreaking findings related to genetic research, contributing significantly to areas such as Drug Discovery, Genetics, Molecular Biology, and Molecular Medicine, as reflected in its Q1 and Q2 quartile rankings throughout 2023. With an ISSN of 1473-9542 and an E-ISSN of 1479-7364, Human Genomics not only delivers high-quality, peer-reviewed research but also ensures accessibility to a broader audience, empowering professionals, students, and academics to stay at the forefront of genomic science. Through its rigorous editorial standards and impactful publications, the journal fosters a collaborative environment for innovative research across the globe from its base in the United Kingdom. By promoting open access since its launch, Human Genomics continues to enhance the visibility and impact of genetic studies, making it an essential resource for anyone involved in the rapidly evolving field of human genomics.

Epigenomics is a leading journal in the realms of Cancer Research and Genetics, published by Future Medicine Ltd in the United Kingdom. With an ISSN of 1750-1911 and an E-ISSN of 1750-192X, the journal has been an integral part of the scientific community since its inception in 2009, and is set to converge its impactful research publications through 2024. The journal occupies a significant position in its category quartiles as evidenced by its ranking—Q3 in Cancer Research and Q2 in Genetics as of 2023. With Scopus rankings of #138/347 in Genetics and #113/230 in Cancer Research, it demonstrates scholarly excellence and is recognized for its contributions to understanding the role of epigenetic modifications in health and disease. While Epigenomics operates under traditional subscription models, it remains a vital resource for researchers, professionals, and students eager to explore the complex interplay between genes and the epigenome. The journal's innovative approach to epigenetics and its impact on cancer research makes it essential reading for those at the forefront of biomedical research.

EUROPEAN JOURNAL OF ENDOCRINOLOGY, published by Oxford University Press, stands as a premier international platform dedicated to advancing research in the burgeoning field of endocrinology, diabetes, and metabolism. Since its inception in 1994, this esteemed journal has gained recognition for its rigorous peer-reviewed articles and innovative studies, evidenced by its impressive Q1 rankings across multiple categories, including Endocrinology and Medicine. With a focus on disseminating critical findings and fostering interdisciplinary collaboration, the journal ranks 33rd out of 244 in Endocrinology, Diabetes, and Metabolism, and 20th out of 128 in Biochemistry, Genetics, and Molecular Biology according to Scopus metrics, positioning it in the top percentiles for researchers worldwide. Although it does not offer open access, the journal remains a vital resource for academics and practitioners alike who seek to stay at the forefront of endocrine research. The EUROPEAN JOURNAL OF ENDOCRINOLOGY continues to push the boundaries of knowledge, driving forward the understanding of complex hormonal functions and their clinical implications.

GENE, an esteemed journal published by Elsevier, serves as a vital resource for researchers and professionals in the fields of genetics and medicine. With an ISSN of 0378-1119 and an E-ISSN of 1879-0038, this scholarly journal has been at the forefront of genetic research since its inception in 1976 and is set to continue until 2025. Situated in the Netherlands, GENE is recognized for its significant contributions, reflected in its Q2 ranking in both Genetics and Miscellaneous Medicine categories for 2023. This positioning within the Scopus rankings demonstrates its impact and relevance in a competitive field, where it holds the rank of #129 out of 347 in Genetics, placing it within the 62nd percentile. Although it does not offer open access options, GENE provides invaluable insight into contemporary genetic research, thereby fostering academic discussions and advancements. Researchers, professionals, and students alike will find GENE an essential platform for disseminating knowledge and exploring innovative developments in genetics and associated sciences.

BIOMEDICAL RESEARCH-TOKYO is an esteemed interdisciplinary journal published by BIOMEDICAL RESEARCH PRESS LTD, dedicated to disseminating pioneering research and advancements in the fields of biochemistry, genetics, and medicine. Since its inception in 1980, the journal has established itself as a reputable source of knowledge, contributing significantly to the global scientific community with its strong emphasis on innovative findings and methodologies. With a consistent presence in the Q3 quartile for both Biochemistry, Genetics and Molecular Biology and Medicine categories as of 2023, it continues to attract a diverse range of research articles. While the journal does not operate as an open access platform, it remains an essential resource for researchers, professionals, and students seeking to further their understanding of biomedical sciences. Located in Sapporo, Japan, this journal fosters collaboration and knowledge sharing among the international biomedical research community, engaging readers through its compelling studies that span from 1980 to 2024.

Genetic Testing and Molecular Biomarkers, an esteemed journal published by MARY ANN LIEBERT, INC, serves as a pivotal platform for advancing the field of genetic research and its applications in medicine. Focused on the innovative intersections of genetics and biomarker discovery, this journal has consistently contributed meaningful insights since its inception in 2009, with its scope evolving through 2024. With an ISSN of 1945-0265 and an E-ISSN of 1945-0257, it offers both traditional and open access options to cater to a broad audience of researchers, professionals, and students. Despite its current classification in the Q4 and Q3 quartiles for Genetics (clinical) and Medicine (miscellaneous) respectively, the journal remains committed to publishing high-quality, peer-reviewed articles that push the boundaries of knowledge in the field. As the landscape of genomic medicine continues to expand, Genetic Testing and Molecular Biomarkers is positioned as a crucial resource for disseminating cutting-edge discoveries and fostering interdisciplinary collaboration.

NEUROPSYCHOPHARMACOLOGY is a prestigious academic journal dedicated to advancing our understanding of the intricate relationship between psychiatric disorders and pharmacological treatments. Published by SpringerNature in the United Kingdom, this leading journal has been a cornerstone in the field since its inception in 1987, with a converged publication timeline extending to 2024. With a remarkable impact factor and illustrious rankings—being positioned 19th in Psychiatry and Mental Health and 16th in Pharmacology—NEUROPSYCHOPHARMACOLOGY is recognized for its rigorous peer-reviewed research that informs clinical practice and enhances therapeutic interventions. The journal is classified in Q1 quartile categories for both Pharmacology and Psychiatry and Mental Health, highlighting its commitment to excellence. Researchers, professionals, and students are encouraged to contribute to this vital dialogue, as the journal does not currently offer open access, emphasizing the importance of curated, high-quality content. By publishing innovative studies and reviews, NEUROPSYCHOPHARMACOLOGY plays a crucial role in shaping the future of mental health treatments and understanding neurobiological mechanisms, making it an indispensable resource for those at the forefront of psychiatric research.

Epigenomes is a distinguished open access journal published by MDPI, dedicated to advancing the field of epigenetics and its interdisciplinary connections to biochemistry, genetics, and molecular biology. Since its inception in 2017, this journal has provided a transparent platform for researchers to share their findings, contributing to a deeper understanding of epigenetic mechanisms and their implications in health, toxicology, and mutagenesis. Ranked in the Q2 quartile across multiple categories, including biochemistry and genetics, Epigenomes is recognized for its scholarly contributions, reflected in its notable Scopus rankings. Readers benefit from a wealth of open access articles, fostering innovation and collaboration within the academic community. With its headquarters in Switzerland and an unwavering commitment to scientific rigor, Epigenomes is positioned as a vital resource for researchers, professionals, and students seeking to deepen their insights into the epigenomic landscape.

BMB Reports is a distinguished open-access journal published by the Korean Society of Biochemistry & Molecular Biology since 2008, making significant contributions to the fields of biochemistry, molecular biology, and medicine. With a current impact factor that positions it in the Q2 category for Biochemistry and Q1 for Miscellaneous Medicine, this journal supports a wide dissemination of high-quality research findings, fostering robust dialogue among researchers, professionals, and students alike. Based in Seoul, South Korea, BMB Reports aims to publish innovative studies that advance our understanding of biochemical and molecular processes, thus shaping the future of health and medicine. The journal's commitment to open access enhances the visibility of its articles, allowing for greater accessibility and engagement in the scientific community. With notable rankings in both the Biochemistry and Molecular Biology categories, BMB Reports stands as a vital resource for those seeking to stay at the forefront of research in these rapidly evolving disciplines.

GENES & DEVELOPMENT, published by COLD SPRING HARBOR LAB PRESS, stands as a premier journal in the fields of Developmental Biology and Genetics, boasting a remarkable impact factor that reflects its prestigious position in the academic community—ranking Q1 in both disciplines as of 2023. Since its inception in 1987, this journal has been at the forefront of disseminating cutting-edge research, effectively bridging the gap between laboratory breakthroughs and their applications in health and disease. Researchers and professionals rely on GENES & DEVELOPMENT for its rigorous peer-review process and its commitment to promoting innovative studies that unravel the complexities of gene functions and developmental processes. With Scopus rankings placing it in the top percentile among its peers, this journal serves as a vital resource for students and established scientists alike, aspiring to expand their knowledge and contribute to the ever-evolving landscape of genetic and developmental research.